Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of APG-3288 in Relapsed/Refractory Blood Cancers [Phase 1]
Phase 1 study of APG-3288 in relapsed/refractory hematologic cancers; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas [Phase 2]
Phase 2 trial evaluating frontline obinutuzumab and ibrutinib in indolent non-Hodgkin lymphoma is active but not recruiting, per ClinicalTri…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Epco, Zanu, Ritux for R/R FL or MZL [Phase 2]
Phase 2 clinical trial recruiting to evaluate Epco, Zanu, and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphom…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas [Phase 3]
This clinical trial update describes a Phase 3 study evaluating reduced-dose radiation therapy for people with B-cell lymphomas, specificall…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. [Phase 1]
A Phase 1 clinical trial evaluating oral LP-168 in relapsed or refractory B-cell malignancies is recruiting. Target conditions include CLL/S…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Study of SGR-1505 in Mature B-Cell Neoplasms [Phase 1]
Schrödinger's SGR-1505 is being evaluated in a Phase 1 trial across multiple mature B-cell neoplasms and is currently recruiting. The study …
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies [Phase 1]
Phase 1 clinical trial from Mayo Clinic is evaluating BAFFR-based CAR-T cells with lymphodepletion (fludarabine and cyclophosphamide) for re…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial assessing the safety of LTZ-301 in patients with various forms of non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas [Phase 2]
A Phase 2 clinical trial evaluating the combination of acalabrutinib and obinutuzumab as initial therapy for previously untreated follicular…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas [Phase 2]
This Phase 2 clinical trial update describes evaluating rituximab in combination with zanubrutinib for indolent B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A clinical trial update describes EO2463, a novel vaccine, being studied as monotherapy and in combination for indolent non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. [Phase 2]
Phase 2 trial investigating orelabrutinib as consolidation and maintenance therapy in treatment-naïve marginal zone lymphoma, currently recr…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
An ongoing clinical trial is evaluating FDG PET imaging as a prognostic tool in marginal zone lymphoma. The study is sponsored by the Intern…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]
A Phase 2 study is evaluating the combination of mosunetuzumab and zanubrutinib in relapsed/refractory marginal zone lymphoma. The trial is …
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma [Phase 2]
Phase 2 clinical trial evaluating response-adapted ultra-low-dose 4 Gy radiation as definitive therapy for Marginal Zone Lymphoma is current…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent …
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma [Phase 3]
Phase 3 randomized trial comparing Mosunetuzumab-Lenalidomide to the investigator's choice in relapsed or refractory marginal zone lymphoma;…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) [Phase 2]
This Phase 2 trial is evaluating pirtobrutinib in combination with rituximab for untreated marginal zone lymphoma and is currently recruitin…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas [Phase 2]
Phase 2 clinical trial update on Pemigatinib in relapsed or refractory B-cell non-Hodgkin lymphomas, including mantle cell lymphoma and marg…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma [Phase 1]
This clinical trial update describes a Phase 1 study of pevonedistat in combination with ibrutinib for relapsed or refractory chronic lympho…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: A Cohort Study in Newly Diagnosed MZL
This clinical trial update reports a cohort study in newly diagnosed marginal zone lymphoma led by Fudan University. The study is currently …
-
CLINICAL_TRIALS research · 2025-11-18Clinical Trial Update: Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma
Ongoing clinical trial evaluating zanubrutinib in combination with rituximab for marginal zone lymphoma; recruitment is currently ongoing.